CureVac
Tuebingen, Germany · StartupCureVac is a biopharmaceutical company based in Tuebingen, Germany, founded in 2000 as a pioneer in mRNA technology. The company was one of the earliest to explore messenger RNA as a therapeutic platform, long before mRNA became a household term during the COVID-19 pandemic. While its first-generation COVID vaccine candidate underperformed in clinical trials, CureVac pivoted to next-generation mRNA technologies and partnered with GSK on a second-generation COVID vaccine and other infectious disease programs. The company is publicly traded on NASDAQ and continues developing its proprietary mRNA optimization platform.